A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC (NCT05968326)
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
Who can join: Review the eligibility criteria below.
Location: USC Norris Comprehensive Cancer Center — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (89 Sites)
Showing the first 25 of 89 sites.
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- USC Norris Cancer Center — Newport Beach, California
- University of California, San Francisco (UCSF) — San Francisco, California
- University of California Los Angeles — Santa Monica, California
- St. Francis Hospital and Medical Center — Hartford, Connecticut
- Smilow Cancer Center — New Haven, Connecticut
- Yale Cancer Center — New Haven, Connecticut
- Smilow Cancer Hospital Care Center at Trumbull — Trumbull, Connecticut
- Northwestern Memorial Hospital — Chicago, Illinois
- Indiana University Health Melvin & Bren Simon Cancer Center — Indianapolis, Indiana
- University of Kentucky Medical Center — Lexington, Kentucky
- Harvard Medical School - Massachusetts General Hospital (MGH) - Cancer Center — Boston, Massachusetts
- Boston Medical Center (BMC) - Cancer Care Center — Boston, Massachusetts
- Henry Ford Health System — Detroit, Michigan
- University of Nebraska — Omaha, Nebraska
- Memorial Sloan Kettering Cancer Center Basking Ridge — Basking Ridge, New Jersey
- Memorial Sloan Kettering Cancer Center — Middletown, New Jersey
- Memorial Sloan Kettering Cancer Center at Bergen — Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center - Commack — Commack, New York
- Memorial Sloan Kettering Cancer Center at Westchester — Harrison, New York
- Northwell Health — Lake Success, New York
- NYU Langone Health — New York, New York
- Mount SInai Medical Center — New York, New York
- Columbia University Medical Center — New York, New York
- MEETH-LHH Northwell Health Cancer Clinical Trials Office at MEETH-LHH — New York, New York
📞 Contact the Study Coordinator
Phone: (888) 662-6728
Email: global-roche-genentech-trials@gene.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Adenocarcinoma, Pancreatic Ductal clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.